Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as the initial development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

The Fiscal Year 2015 Department of Defense Appropriations Act provides research funding for the following peer reviewed programs managed by the Department of Defense office of Congressionally Directed Medical Research Programs (CDMRP): Alcohol and Substance Abuse Research Program - $4.0 million Amyotrophic Lateral Sclerosis Research Program - $7.5 million Autism Research Program - $6.0 million Bone Marrow Failure Research Program - $3.2 million Breast Cancer Research Program - $120.0 million Duchenne Muscular Dystrophy Research Program - $3.2 million Epilepsy Research Program - $7.5 million Gulf War Illness Research Program - $20.0 million Joint Warfighter Medical Research Program - $50.0 million Lung Cancer Research Program - $10.5 million Military Burn Research Program - $8.0 million Multiple Sclerosis Research Program - $5.0 million Neurofibromatosis Research Program - $15.0 million Neurotoxin Exposure Treatment Parkinson's Research Program - $16.0 million Orthotics and Prosthetics Outcomes - $10.0 million Ovarian Cancer Research Program - $20.0 million Peer Reviewed Alzheimer's Research Program - $12.0 million Peer Reviewed Cancer Research Program - $50.0 million Peer Reviewed Medical Research Program - $247.5 million Peer Reviewed Orthopaedic Research Program - $30.0 million Prostate Cancer Research Program - $80.0 million Spinal Cord Injury Research Program - $30.0 million Tuberous Sclerosis Complex Research Program - $6.0 million Vision Research Program - $10.0 million

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 in support of researchers with a novel approach to pediatric oncology investigation. This can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of successfully competing for extramural funding. To be eligible, applicants must possess a degree at the MD, MD/PhD or PhD level and hold a faculty appointment at an academic institution.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key downstream consequences for single (e.g., genetic testing consent) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage scientific disciplines that have not traditionally conducted cancer research such as affective and cognitive neuroscience, decision science, and consumer science to elucidate perplexing and understudied problems in basic affective and decision sciences with promise of having downstream implications for cancer prevention and control science.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

The Caring for Carcinoid Foundation-AACR Grant for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research represents a joint effort to promote and support innovative cancer research. This grant is available to full time, independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to carcinoid tumors or pancreatic neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, clinical, or epidemiological cancer research. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to carcinoid tumor or pancreatic neuroendocrine tumor research.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.

The annual Pancreatic Cancer Action Network-AACR Pathway to Leadership grant program represents a joint effort to ensure the future leadership of pancreatic cancer research by supporting outstanding early career investigators, beginning in their postdoctoral research positions and continuing through their successful transition to independent research. A five-year grant of up to $600,000 will be awarded to support a highly promising postdoctoral or clinical research fellow who is in the mentored research phase and ready to transition to an independent research career.

The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure, or treatment of primary brain tumors/brain cancer. The annual award provides up to $600,000 in funding over a four-year period. Over that time, recipients also receive additional support from the foundation through its network of scientists in the field and an annual alumni conference.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

The Brain Tumor Funders' Collaborative works to identify potential therapies for patients with primary human brain tumors, with the goal of increasing progression-free patient survival and improving quality of life for patients affected by a primary brain tumor. To that end, BTFC has issued a Request for Proposals for research on the role of the neuro-immune system in the origin and progression of immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. Priority will be given to studies on immune responses in primary brain tumors in pediatric and/or adult human patients. The program, which will provide grants of up to $250,000 per year over three years, will support a small number of multidisciplinary team-based projects. Teams should represent the requisite skills needed to carry out the proposed research, including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained, including radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma).